2026-03-19 10:02:59
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results with Promising Clinical Data
Expected Stock impact: Noticeably Positive
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has announced its financial results for the year ended December 31, 2025, along with significant corporate updates. The company reported a net loss of $12.2 million for the year, compared to a net loss of $10.7 million in 2024. Despite the losses, the company highlighted encouraging clinical data from its Phase 1 APOLLO study, which demonstrated a 66% objective response rate in patients with relapsed non-Hodgkin lymphoma, including a 50% complete response rate. This data is expected to positively influence the company's stock price as it indicates strong potential for their lead Multi-Antigen Recognizing (MAR)-T cell therapy, MT-601. Additionally, Marker Therapeutics has made strides in expanding its research into pancreatic cancer, supported by a publication in Nature Medicine that showcased promising results for multi-antigen targeted T cells. The company also strengthened its manufacturing capabilities through a collaboration with Cellipont Bioservices and expanded its Board of Directors with the appointment of Kathryn Penkus Corzo. Looking ahead, Marker anticipates continued clinical execution and plans to provide further updates from the APOLLO study in the second quarter of 2026, which could further enhance investor confidence and stock performance.
